NCT05319873 2025-05-13
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT03054363 2023-11-13
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
University of Colorado, Denver
Phase 1/2 Completed
NCT04896320 2023-06-22
2019-101826
Providence Health & Services
Phase 1/2 Withdrawn
NCT04512261 2022-07-01
TOPAZ
Cedars-Sinai Medical Center
Phase 1/2 Withdrawn